The SARAH Study
The European SARAH Study with 467 patients showed that compared with standard treatment of sorafenib, local treatment of advanced or inoperable Hepatocellular Carcinoma (HCC) with SIR-Spheres® Y-90 resin microspheres:
- did not lead to a significant improvement in overall survival
- significantly reduced the frequency and severity of side effects
- was significantly better tolerated
- was associated with a significantly better Quality of Life
Vilgrain V et al. Lancet Oncol 2017 October 26; ePub: doi.org/10.1016/S1470-2045(17)30683-6.